Published in Medical Letter on the CDC and FDA, March 20th, 2005
Under the terms of the financing, in exchange for gross proceeds of approximately $3.77 million, DOR will issue, subject to customary closing conditions, 8,396,100 shares of common stock and warrants to purchase 6,297,075 shares of common stock.
The warrants, which will have an exercise price of 101% of the closing price per share of the company's common stock on the closing date, will be exercisable for a period of 5 years...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.